Latest Trastuzumab Stories
A study headed up by the Vall d'Hebron Institute of Oncology (VHIO) heralds a new horizon in the fight against cancer, opening up a parallel dimension to existing treatment options.
Breast cancers expressing the protein HER2 have a particularly poor prognosis.
Using two drugs that inhibit the growth factor HER2 for preoperative treatment of early-stage HER2-positive breast cancer appears to have better results than treatment with a single agent.
Precisely quantifying the amount of three different HER growth proteins, along with several other proteins believed linked to breast cancer, did not predict a patient's outcome after treatment for HER2-Positive Breast Cancer with Herceptin, say Mayo Clinic researchers.
Initial results from an ongoing clinical trial, the first designed to examine the utility of whole-genome sequencing for triple negative breast cancer.
- A political dynamiter.